Looks like IBB and XBI took the brunt of the weigh
Post# of 72440
(Total Views: 706)
Posted On: 09/24/2020 4:25:18 PM
Looks like IBB and XBI took the brunt of the weight today driving bios down.
Thing is, we're actually in pretty good shape. So many stress about the markets. If you know what you own, you see opportunity, not panic. I know some of you old geezers know exactly what I'm trying to convey.
IPIX won't be standing alone for long imo. Let the peer review come out and watch the grant roll in for the RBL and for UCSF (which could happen overnight imo with a simple request).
I really didn't mean to express that brilacidin doesn't meet the potential to compete with the big dogs. One by one the big dogs are showing a lack of luster and the vaccine that whoever comes up with will not be a full vaccine (side effects showing so far from contracting COVID) when actually exposed to the virus. It'll be YEARS before this is thought of as history. Therapeutics, like brilacidin will be THE KEY to reducing and/or eliminating those side effects.
Looking forward to seeing the protocol and seeing what sites the trial will be.
Also, as a side note, I saw someone mention the lack of news about our partnership with Alfasigma. I'm thinking that dog is certainly still in the running. $24M in milestones at the starting gate there. It'll come out of no where what we hear next imo..
Anyway, yes, I AM still buying IPIX.
Thing is, we're actually in pretty good shape. So many stress about the markets. If you know what you own, you see opportunity, not panic. I know some of you old geezers know exactly what I'm trying to convey.
IPIX won't be standing alone for long imo. Let the peer review come out and watch the grant roll in for the RBL and for UCSF (which could happen overnight imo with a simple request).
I really didn't mean to express that brilacidin doesn't meet the potential to compete with the big dogs. One by one the big dogs are showing a lack of luster and the vaccine that whoever comes up with will not be a full vaccine (side effects showing so far from contracting COVID) when actually exposed to the virus. It'll be YEARS before this is thought of as history. Therapeutics, like brilacidin will be THE KEY to reducing and/or eliminating those side effects.
Looking forward to seeing the protocol and seeing what sites the trial will be.
Also, as a side note, I saw someone mention the lack of news about our partnership with Alfasigma. I'm thinking that dog is certainly still in the running. $24M in milestones at the starting gate there. It'll come out of no where what we hear next imo..
Quote:
On July 18, 2019, the Company entered into an Exclusive License Agreement (the “License Agreement”) with Alfasigma S.p.A., a global pharmaceutical company (“Alfasigma”), granting Alfasigma the worldwide right to develop, manufacture and commercialize locally-administered Brilacidin for the treatment of ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS).
Anyway, yes, I AM still buying IPIX.
(2)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼